<DOC>
	<DOCNO>NCT02784392</DOCNO>
	<brief_summary>The purpose study evaluate effect Ulimorelin patient enteral feed intolerance .</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetics ( PK ) Study Ulimorelin Patients With Enteral Feeding Intolerance ( EFI ) : The PROMOTE Trial</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , comparator-controlled study . The study consist 2 parallel-dose treatment group consist ulimorelin metoclopramide . Approximately 120 mechanically ventilate , tube-fed patient EFI participate trial . To eligible study participation , patient must intolerant continuous gastric tube feeding , intolerance define gastric residual volume ( GRV ) ≥ 500 mL one measurement .</detailed_description>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Men nonpregnant woman age 18 year Intubated mechanically ventilated ICU Receiving continuous nasogastric , orogastric , percutaneous gastric tube feeding , contraindication advance feeding per feed protocol A 12Fr large nasogastric , orogastric , percutaneous gastric feeding tube , distal tip least 10 cm gastroesophageal junction visible stomach routine radiographic examination within 24 hour screen Enteral feed intolerance , define GRV ≥ 500 mL one measurement Expected remain intubated , mechanically ventilate , receive nasogastric feed least 72 hour Inability obtain write informed consent participate study patient legally authorize representative Prior use current ICU admission parenteral nutrition trophic feeding , define prescription receive ≤ 20 mL/hr enteral feed 24 hour prior screen [ N.B. , parenteral nutrition may initiate post randomization provide supplemental nutrition coordinate calorie protein target Prescribed Total Volume ( PTV ) reduce enteral feeding advance ] Weight prior ICU admission exceed 150.0 kg Suspicion confirmation active bowel obstruction , perforation , leakage History esophageal gastric surgery prior current hospital admission Use follow prokinetic medication current ICU admission : domperidone , cisapride , neostigmine , opioid antagonist , include alvimopan , naloxone , naltrexone , analogs naloxone naltrexone ; erythromycin azithromycin [ N.B. , azithromycin permit treatment pulmonary infection 48 hour randomization , thereafter Day 5 . Up 2 dos metoclopramide permit , provide drug administer within 10 hour first dose study drug time Day 5 . If patient receives metoclopramide screen period , radiologic examination must confirm feed tube remain visible stomach final dose drug screen prior start baseline gastric empty measurement migrate duodenum . Use clarithromycin indication exclude . Propofol must discontinue screening . However , use may permit special circumstance subsequent first dose study drug excess 12 hour administration 5day study period . ] Patient 's clinical condition deteriorate rapidly , Investigator consider reasonable expectation patient complete study Childs C cirrhosis Alanine Aminotransferase ( ALT ) ≥1000 U/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>